Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Silo Pharma (SILO) over the last 12 years, with Q3 2025 value amounting to -$18.6 million.

  • Silo Pharma's Retained Earnings fell 3751.12% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.6 million, marking a year-over-year decrease of 3751.12%. This contributed to the annual value of -$15.3 million for FY2024, which is 4040.61% down from last year.
  • As of Q3 2025, Silo Pharma's Retained Earnings stood at -$18.6 million, which was down 3751.12% from -$17.5 million recorded in Q2 2025.
  • In the past 5 years, Silo Pharma's Retained Earnings ranged from a high of -$2.2 million in Q3 2021 and a low of -$18.6 million during Q3 2025
  • Moreover, its 5-year median value for Retained Earnings was -$9.1 million (2023), whereas its average is -$9.8 million.
  • The largest annual percentage gain for Silo Pharma's Retained Earnings in the last 5 years was 5628.18% (2021), contrasted with its biggest fall of 17972.06% (2021).
  • Quarter analysis of 5 years shows Silo Pharma's Retained Earnings stood at -$3.3 million in 2021, then plummeted by 119.8% to -$7.2 million in 2022, then tumbled by 51.61% to -$10.9 million in 2023, then crashed by 40.41% to -$15.3 million in 2024, then decreased by 21.92% to -$18.6 million in 2025.
  • Its Retained Earnings was -$18.6 million in Q3 2025, compared to -$17.5 million in Q2 2025 and -$16.3 million in Q1 2025.